Claims
- 1. A method of controlling or treating an illness which comprises administering to a patient an effective amount of a compound of the formula I: in which or a physiologically acceptable salt thereof,wherein the illness is asthma, an allergic disease, an inflammatory disease, an autoimmune disease, a transplant rejection reaction, an illness in which an increase in the cAMP levels leads to inhibition or prevention of inflammation and muscle relaxation and/or an illness controlled or treated by inhibition of phosphodiesterase IV.
- 2. The method of claim 1, wherein the compound of the formula I administered is in the form a separated enantiomer.
- 3. The method of claim 1, wherein the compound of formula I isa) 2-(4-ethoxycarbonylaminobenzyl)-6-(3,4-di-methoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one; b) 2-(3-methylsulfonamidobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one; c) 2-(3-acetamidobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one; d) 2-(4-trifluoroacetamidobenzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one; e) 2-(4-ethoxycarbonylaminobenzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one; f) 2-(4-methoxycarbonylaminobenzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one; or g) 2-(4-butyrylaminobenzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one.
- 4. A method of claim 1, wherein the compound of the formula I and/or one of its physiologically acceptable salts is administered in a composition also containing at least one solid, liquid or semi-liquid excipient or auxiliary.
- 5. The method of claim 1, wherein the illness is asthma.
- 6. The method of claim 1, wherein the illness is an allergic disease, inflammatory disease, autoimmune disease or transplant rejection reaction.
- 7. The method of claim 1, wherein the illness is one in which an increase in the cAMP levels leads to inhibition or prevention of inflammation and muscle relaxation.
- 8. The method of claim 1, wherein the illness is controlled or treated by inhibition of phosphodiesterase IV.
- 9. The method of claim 1, wherein the compound administered is of the formula I where R1 is H, R2 is H or A, and R3 is OA.
- 10. The method of claim 1, wherein the compound administered is of the formula I where R1 is H, R2 is methyl or ethyl, and R3 and R4 are each independently of one another OA.
- 11. The method of claim 1, wherein the compound administered is of the formula I where R1 is H, R2 is H or A, and R3 is OA, and R4 is OA where A is mono- di- or trifluoro-substituted alkyl having 1 to 6 C atoms.
- 12. The method of claim 1, wherein the compound administered is of the formula I where R1 is H, R2 is methyl or ethyl, and R3 and R4 are each independently of one another OR10.
- 13. The method of claim 1, wherein the compound administered is of the formula I where R1 and R2 are each H, and R3 and R4 each independently of one another are OA.
Priority Claims (1)
Number |
Date |
Country |
Kind |
195 14 568 |
Apr 1995 |
DE |
|
Parent Case Info
This application is a divisional of U.S. patent application Ser. No. 08/634,830, filed Apr. 19, 1996, now U.S. Pat. No. 6,399,611.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
4289774 |
Schacht et al. |
Sep 1981 |
A |
4666902 |
Zoller et al. |
May 1987 |
A |
4816454 |
Zoller et al. |
Mar 1989 |
A |
4954499 |
Prücher |
Sep 1990 |
A |
Foreign Referenced Citations (5)
Number |
Date |
Country |
2168193 |
Jul 1996 |
CA |
0 186 484 |
Jul 1986 |
EP |
0 412 814 |
Feb 1991 |
EP |
0 667 158 |
Aug 1995 |
EP |
0 383 449 |
Sep 1995 |
EP |
Non-Patent Literature Citations (1)
Entry |
L. Pitarch et al., Eur. J. Med. Chem.—Chimica Therapeutica, vol. 6, No. 6, pp. 644-646 (1974). |